Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide capable of regulating glycometabolism and application thereof

A technology of sugar metabolism and peptides, applied in the field of biomedicine, can solve problems such as deficiency and insulin resistance

Active Publication Date: 2017-06-27
深圳中科新进生物科技有限公司
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Type 2 diabetes, also known as non-insulin-dependent diabetes, usually develops after the age of 35-40. The ability to produce insulin in the body is not completely lost or even compensatoryly increased, but insulin resistance occurs in the body, resulting in a relative deficiency.
[0003] Currently, there is no cure for type 2 diabetes, and the drug must be accompanied for a lifetime and has other side effects. Therefore, the current treatment of diabetes still has great defects, and new drugs with better performance need to be developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide capable of regulating glycometabolism and application thereof
  • Polypeptide capable of regulating glycometabolism and application thereof
  • Polypeptide capable of regulating glycometabolism and application thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0084] DMEM medium was purchased from Sigma, wherein every 500ml medium supplemented with 10% FBS (fetal bovine serum), 1% non-essential amino acids, 1g glucose, 0.75g sodium bicarbonate, 0.1g bovine serum albumin and 1.5ml HEPES (4 -Hydroxyethylpiperazineethanesulfonic acid).

[0085] ISAPs 1 The sequence is Tyr-Leu-Gly-Ala-Ser-Val-Pro-Ser-Pro-Asp-Pro-Leu-Glu-Pro-Thr (SEQ ID NO. 22). ISAPs 2 The sequence is Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Ser-Val-Pro-Ser-Pro-Asp-Pro-Leu-Glu-Pro (SEQ ID NO.2). ISAPs 3 The sequence is Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Ser-Val-Pro-Ser-Pro-Asp-Pro-Leu-Glu-Pro-Arg (SEQ ID NO.3). ISAPs 4 The sequence is Ser-Val-Pro-Ser-Pro-Asp-Pro-Leu-Glu-Pro (SEQ ID NO.15). ISAPs 5 The sequence is Pro-Ser-Pro-Asp-Pro-Leu-Glu-Pro (SEQ ID NO.16). ISAPs 6 The sequence is Pro-Asp-Pro-Leu-Glu-Pro (SEQ ID NO.14).

[0086] βTC-6 was purchased from the American Type Culture Collection (ATCC). This cell line is derived from mouse pancreatic cancer and has introduce...

Embodiment 1

[0089] ISAPs 1 function of

[0090] 1. ISAPs 1 Effects on βTC-6 cells.

[0091] The experimental steps are as follows:

[0092] 1. Cell plating: Dilute the βTC-6 cell suspension at 1.6×10 5 / mL density plated in 24-well plates, 0.5 mL per well, at 37 °C, 5% CO 2 Incubate for 24 hours.

[0093] 2. Mix ISAP with sugar-free DMEM 1 Dilute to 2nmol / L, 200pmol / L, 20pmol / L, 2pmol / L respectively and store in ice bath.

[0094] 3. Perform starvation pretreatment on βTC-6 cells, using KRBB buffer (129g NaCl, 5g NaHCO 3 ,4.8gKCl,1.2gKH 2 PO 4 ,1.2g MgSO 4 ,2.5g CaCl 2 , 10mM HEPES and 0.1% BSA at pH 7.4) for 4 hours.

[0095] 4. The cell culture medium was discarded, and ISAP containing different concentrations were added to the experimental group and the positive control group respectively. 1 and glucose culture solution, the negative control group only added medium (blank), at 37 ° C, 5% CO 2 Neutralize for 1 hour.

[0096] 5. Wash the cells at the bottom of the plate twic...

Embodiment 2

[0125] ISAPs 2 The function ISAP 2 Binding to human GPRC6A

[0126] 2.1 Overexpression of hGPRC6A in Hela cells 1) Cell plating: Hela cell suspension was mixed with 1.6×10 5 / mL density plated in 6-well plates, 2 mL per well of DMEM medium, at 37 °C, 5% CO 2Incubate for 24 hours.

[0127] 2) Using Lipofectamine2000 (Invitrogen), the hGPRC6 overexpression vector (pReceiver-M61) was transfected into Hela cells according to the manufacturer's instructions, and the normal medium was replaced 4 hours after transfection.

[0128] 3) 48 hours after transfection, discard the medium, wash the cells at the bottom of the plate twice with sterile PBS, add 300 μL of Trizol solution, extract cellular RNA according to the instructions of RNAiso Plus (TaKaRa), after DNase treatment, use SuperScript T (Invitrogen, Canada) kit was reverse transcribed into cDNA by DNAEngine. Using cDNA as a template, the fluorescent PCR products at each time point were monitored and analyzed by SYBRGreen me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a polypeptide capable of regulating glycometabolism and application thereof to preparation of medicines for treating diseases related to the glycometabolism. The polypeptide can lower blood sugar and promote insulin secretion, can be applied to preparation of medicines for treating diabetes, and can be combined with the existing therapeutic schemes for use. The polypeptide has the significant advantages as follows: the polypeptide is low in therapeutic effective dose, can be orally administered and the like.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a polypeptide regulating sugar metabolism and its use in preparing medicines for treating diseases related to abnormal sugar metabolism. Background technique [0002] Diabetes is a major and growing health problem worldwide. Diabetes mellitus is a chronic disease of carbohydrate, fat and protein metabolism disorder caused by relative or absolute deficiency of insulin or decreased sensitivity of target cells to insulin, or structural defects of insulin itself. Diabetes is clinically manifested as polydipsia, polyphagia, polyuria, and weight loss, accompanied by various complications such as ketoacidosis, limb gangrene, polyneuritis, blindness, and renal failure. According to the pathogenesis, diabetes can be divided into type 1 and type 2, and 95% of the patients are type 2. Type 2 diabetes, also known as non-insulin-dependent diabetes, usually occurs after the age of 35-40. The abi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47C12N15/12A61K38/17A61P3/08A61P3/10A61P5/50
CPCC07K14/4728A61K38/00
Inventor 任培根张键滕斌李健姚振宇
Owner 深圳中科新进生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com